• NEBANNER

Low MOQ for Ciprofloxacin Hcl 93107-08-5 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Low MOQ for Ciprofloxacin Hcl 93107-08-5 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We emphasize progress and introduce new merchandise into the market each and every year for Purification Of Water, Cooling Tower Chemicals, Endogenous Analgesia, We'll do our greatest to fulfill your specifications and are sincerely searching ahead to developing mutual helpful small business marriage with you!
Low MOQ for Ciprofloxacin Hcl 93107-08-5 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN Detail:

Used in adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

It is used to prevent or reduce the formation of thrombosis, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery.

The recommended dose is oral rivaroxaban 10mg, once a day. Rivaroxaban 10mg can be taken with food or alone. Rivaroxaban 15mg or 20mg tablets should be taken with food.

standard: usp40
Assay: 99-102%

Exterior: White powder
Package : 25kg/drum

Take 4-(4-aminophenyl) morpholin-3-one (SM-1), (S)-N-glycidyl phthalimide (SM-2), 5-chlorothiophene-2- Formyl chloride (SM-3) is the starting material. After condensation, cyclization, aminolysis and acylation, the crude rivaroxaban is obtained, and the finished rivaroxaban is refined.
Preparation: This product is a red film-coated tablet.

Accessories:
Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium lauryl sulfate, magnesium stearate
Coating: polyethylene glycol, hypromellose, titanium dioxide, iron oxide red

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. Through highly selective and competitive inhibition of free and bound factor Xa and prothrombin activity, prolong the activated partial thromboplastin time plate (PT) and prothrombin time (aPTT) in a dose-dependent manner, which can interrupt the coagulation waterfall The endogenous and exogenous pathways inhibit the production of thrombin and thrombosis. Rivaroxaban does not inhibit thrombin (activating factor Ⅱ), nor has it proven to have an effect on platelets
The essential difference between rivaroxaban and fondaparinux/heparin is that it does not require the participation of antithrombin III and can directly antagonize free and bound factor Xa; while heparin requires antithrombin III to function, and It has no effect on factor Xa in the prothrombin complex.


Product detail pictures:

Low MOQ for Ciprofloxacin Hcl 93107-08-5 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN detail pictures


Related Product Guide:

"Sincerity, Innovation, Rigorousness, and Efficiency" is the persistent conception of our firm to the long-term to develop together with consumers for mutual reciprocity and mutual advantage for Low MOQ for Ciprofloxacin Hcl 93107-08-5 - Rivaroxaban(S)-Rivaroxaban;BAY 59-7939;RivaroxabanIsomer;Rivaroxaban; – JIN DUN , The product will supply to all over the world, such as: Sacramento, Karachi, Algeria, With the first-class products, excellent service, fast delivery and the best price, we have won highly praise foreign customers'. Our products have been exported to Africa, the Middle East, Southeast Asia and other regions.
  • The company's products can meet our diverse needs, and the price is cheap, the most important is that the quality is also very nice.
    5 Stars By Madeline from Jordan - 2018.12.11 14:13
    The sales person is professional and responsible, warm and polite, we had a pleasant conversation and no language barriers on communication.
    5 Stars By Erica from Greek - 2018.12.25 12:43
    Write your message here and send it to us